Paradigm BiopharmaceuticalsASX:PAR -3.13%28 Gross Margin % is 84.00% as of Dec. 2025, which is 41% above its 10-year median of 59.57. GuruFocus rates ASX:PAR with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 737 Biotechnology companies, Paradigm Biopharmaceuticals ranks better than 86.57% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Paradigm Biopharmaceuticals had a gross margin of 84.00% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Paradigm Biopharmaceuticals Gross Margin % Related Terms
Paradigm Biopharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PAR vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paradigm Biopharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Paradigm Biopharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Paradigm Biopharmaceuticals (ASX:PAR) has a Gross Margin % of 84.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Paradigm Biopharmaceuticals and its competitors. This is 41% above median its historical median of 59.57. According to the industry distribution chart, Paradigm Biopharmaceuticals ranks #99 out of 737 companies in the Biotechnology industry, placing it in the top 13.4%.
Is Paradigm Biopharmaceuticals' Gross Margin % too high?
Paradigm Biopharmaceuticals' current Gross Margin % of 84.00% is 41% above median its 10-year median of 59.57. The Biotechnology industry median Gross Margin % is 60.92. Paradigm Biopharmaceuticals' value of 84.00% is 37.9% above this industry median. Based on the distribution chart, Paradigm Biopharmaceuticals ranks #99 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Paradigm Biopharmaceuticals ranks #99 out of 737 companies for Gross Margin %. This places Paradigm Biopharmaceuticals in the top 13% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Paradigm Biopharmaceuticals' value of 84.00% is 37.9% above this benchmark. While the company's 10-year median is 59.57 vs. the industry median of 60.92, Paradigm Biopharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paradigm Biopharmaceuticals's current Gross Margin % of 84.00% is 37.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Paradigm Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paradigm Biopharmaceuticals's current Gross Margin % is 84.00%, which is 41% above median its own 10-year median of 59.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Gross Margin % of 84.00%. The current Gross Margin % is 84.00%, which is 41% above median its 10-year median of 59.57 and 37.9% above the Biotechnology industry median of 60.92. Paradigm Biopharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Gross Margin % is 84.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
28GF Score
Get the complete analysis for ASX:PAR
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PAR has been successfully added to your 
